284 related articles for article (PubMed ID: 24463035)
1. Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects.
Khodr CE; Becerra A; Han Y; Bohn MC
Brain Res; 2014 Mar; 1550():47-60. PubMed ID: 24463035
[TBL] [Abstract][Full Text] [Related]
2. An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons.
Khodr CE; Sapru MK; Pedapati J; Han Y; West NC; Kells AP; Bankiewicz KS; Bohn MC
Brain Res; 2011 Jun; 1395():94-107. PubMed ID: 21565333
[TBL] [Abstract][Full Text] [Related]
3. Inclusion of a portion of the native SNCA 3'UTR reduces toxicity of human S129A SNCA on striatal-projecting dopamine neurons in rat substantia nigra.
Khodr CE; Pedapati J; Han Y; Bohn MC
Dev Neurobiol; 2012 Jun; 72(6):906-17. PubMed ID: 22021082
[TBL] [Abstract][Full Text] [Related]
4. A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons.
Han Y; Khodr CE; Sapru MK; Pedapati J; Bohn MC
Brain Res; 2011 Apr; 1386():15-24. PubMed ID: 21338582
[TBL] [Abstract][Full Text] [Related]
5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of tyrosine hydroxylase phenotype after AAV injection above substantia nigra: Caution in experimental models of Parkinson's disease.
Albert K; Voutilainen MH; Domanskyi A; Piepponen TP; Ahola S; Tuominen RK; Richie C; Harvey BK; Airavaara M
J Neurosci Res; 2019 Mar; 97(3):346-361. PubMed ID: 30548446
[TBL] [Abstract][Full Text] [Related]
7. Long-term RNAi knockdown of α-synuclein in the adult rat substantia nigra without neurodegeneration.
Zharikov A; Bai Q; De Miranda BR; Van Laar A; Greenamyre JT; Burton EA
Neurobiol Dis; 2019 May; 125():146-153. PubMed ID: 30658149
[TBL] [Abstract][Full Text] [Related]
8. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein.
Koprich JB; Johnston TH; Huot P; Reyes MG; Espinosa M; Brotchie JM
PLoS One; 2011 Mar; 6(3):e17698. PubMed ID: 21408191
[TBL] [Abstract][Full Text] [Related]
9. Morphological and behavioral impact of AAV2/5-mediated overexpression of human wildtype alpha-synuclein in the rat nigrostriatal system.
Gombash SE; Manfredsson FP; Kemp CJ; Kuhn NC; Fleming SM; Egan AE; Grant LM; Ciucci MR; MacKeigan JP; Sortwell CE
PLoS One; 2013; 8(11):e81426. PubMed ID: 24312298
[TBL] [Abstract][Full Text] [Related]
10. ser31 Tyrosine hydroxylase phosphorylation parallels differences in dopamine recovery in nigrostriatal pathway following 6-OHDA lesion.
Salvatore MF
J Neurochem; 2014 May; 129(3):548-58. PubMed ID: 24410633
[TBL] [Abstract][Full Text] [Related]
11. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
[TBL] [Abstract][Full Text] [Related]
12. Heat shock protein 70 reduces α-synuclein-induced predegenerative neuronal dystrophy in the α-synuclein viral gene transfer rat model of Parkinson's disease.
Moloney TC; Hyland R; O'Toole D; Paucard A; Kirik D; O'Doherty A; Gorman AM; Dowd E
CNS Neurosci Ther; 2014 Jan; 20(1):50-8. PubMed ID: 24279716
[TBL] [Abstract][Full Text] [Related]
13. Reduced TH expression and α-synuclein accumulation contribute towards nigrostriatal dysfunction in experimental hepatic encephalopathy.
Suárez I; Bodega G; Rubio M; Fernández B
Restor Neurol Neurosci; 2017; 35(5):469-481. PubMed ID: 28984618
[TBL] [Abstract][Full Text] [Related]
14. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.
Chung CY; Koprich JB; Siddiqi H; Isacson O
J Neurosci; 2009 Mar; 29(11):3365-73. PubMed ID: 19295143
[TBL] [Abstract][Full Text] [Related]
15. AAV.shRNA-mediated downregulation of ROCK2 attenuates degeneration of dopaminergic neurons in toxin-induced models of Parkinson's disease in vitro and in vivo.
Saal KA; Koch JC; Tatenhorst L; Szegő EM; Ribas VT; Michel U; Bähr M; Tönges L; Lingor P
Neurobiol Dis; 2015 Jan; 73():150-62. PubMed ID: 25283984
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of alpha-synuclein expression can rescue dopaminergic cells from cell death in the substantia nigra of Parkinson's disease rat model.
Hayashita-Kinoh H; Yamada M; Yokota T; Mizuno Y; Mochizuki H
Biochem Biophys Res Commun; 2006 Mar; 341(4):1088-95. PubMed ID: 16460685
[TBL] [Abstract][Full Text] [Related]
17. Monoamine Oxidase-B Inhibition Facilitates α-Synuclein Secretion
Nakamura Y; Arawaka S; Sato H; Sasaki A; Shigekiyo T; Takahata K; Tsunekawa H; Kato T
J Neurosci; 2021 Sep; 41(35):7479-7491. PubMed ID: 34290084
[TBL] [Abstract][Full Text] [Related]
18. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra.
St Martin JL; Klucken J; Outeiro TF; Nguyen P; Keller-McGandy C; Cantuti-Castelvetri I; Grammatopoulos TN; Standaert DG; Hyman BT; McLean PJ
J Neurochem; 2007 Mar; 100(6):1449-57. PubMed ID: 17241127
[TBL] [Abstract][Full Text] [Related]
19. T cell infiltration and upregulation of MHCII in microglia leads to accelerated neuronal loss in an α-synuclein rat model of Parkinson's disease.
Subbarayan MS; Hudson C; Moss LD; Nash KR; Bickford PC
J Neuroinflammation; 2020 Aug; 17(1):242. PubMed ID: 32799878
[TBL] [Abstract][Full Text] [Related]
20. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
